Morphea associated with the use of adalimumab: A case report and review of the literature

Modern Rheumatology

Volumn 22, Issue 4, 2012, Pages 602-604

  Ramírez, Julio ^a   Hernández, M Victoria ^a   Galve, Javier ^a   Canete, Juan D ^a   Sanmartí, Raimon ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Ankylosing spondylitis; Antirheumatic agents; Drug toxicity; Localized scleroderma; Tumor necrosis factor alpha

Indexed keywords

ADALIMUMAB; CLOBETASOL PROPIONATE; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CASE REPORT; CROHN DISEASE; DRUG EFFICACY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ERYTHEMA; HUMAN; HUMAN TISSUE; HYPERPIGMENTATION; LABORATORY TEST; LEG; LYMPHOCYTIC INFILTRATION; MALE; MEDICAL LITERATURE; MINIMAL RESIDUAL DISEASE; MORPHEA; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SCLERODERMA; SIDE EFFECT; SKIN BIOPSY; SKIN EDEMA; SKIN INDURATION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; HUMANS; LOWER EXTREMITY; MALE; SCLERODERMA, LOCALIZED; SKIN; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA; WITHHOLDING TREATMENT;

EID: 84865389552     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0550-4     Document Type: Article

References (17)

1. Borrás-Blasco J, Navarro-Ruiz A, Borrás C, Casterá E. Adverse cutaneous reactions induced by TNF-alpha antagonist therapy. South Med J. 2009;102:1133-40.
2. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-a-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther. 2005;7:R666-76.
3. Lee HH, Song IH, Friedich M, et al. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-a antagonists. Br J Dermatol. 2007;156:486-91.
4. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy. A randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004;50:1400-11. (Pubitemid 38608061)
5. Dalmau J, Roé E, Corella F, García-Navarro X, Peramiquel L, Alomar A. Acute generalized skin eruption due to adalimumab: report of two cases. J EurAcadDermatolVenereol. 2007;21:1105-6. (Pubitemid 47304614)
6. García Bartels N, Lee HH, Worm M, Burmester GR, Sterry W, Blume-Peytavi U. Development of alopecia areata universalis in a patient receiving adalimumab. Arch Dermatol. 2006;142:1654-5. (Pubitemid 44969233)
7. Rajpara SN, Ormerod AD, Gallaway L. Adalimumab-induced pityriasis rosea. J Eur Acad Dermatol Venereol. 2007;21:1294-6.
8. Nikas SN, Voulgari PV, Drosos AA. Urticaria and angioedemalike skin reactions in a patient treated with adalimumab. Clin Rheumatol. 2007;26:787-8. (Pubitemid 46554095)
9. Beuthien W, Mellinghoff HH, von Kempis J. Skin reaction to adalimumab. Arthritis Rheum. 2004;50:1690-2. (Pubitemid 38608093)
10. Salama M, Lawrance IC. Stevens-Johnson syndrome complicating adalimumab therapy in Crohn's disease. World J Gastroenterol. 2009;15:4449-52.
11. FDA US Food and drug administration. Tumor necrosis factor alpha (TNF-a) antagonists [infliximab (marketed as REMICADE), etanercept (marketed as ENBREL), and adalimumab (marketed as HUMIRA)]: serious skin reactions. Postmarketing Rev. 2008;1(2). http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ ucm119034.htm#tnf.
12. Ranganathan P. Infliximab-induced scleroderma in a patient with rheumatoid arthritis. J Clin Rheumatol. 2005;11:319-22. (Pubitemid 44384023)
13. Mattozzi C, Richetta AG, Cantisani C, et al. Morphea, an unusual side effect of anti-TNF-alpha treatment. Eur J Dermatol. 2010;20: 400-1.
14. Zulian F. New developments in localized scleroderma. Curr Opin Rheumatol. 2008;20:601-7.
15. Badea I, Taylor M, Rosenberg A, Foldvari M. Pathogenesis and therapeutic approaches for improved topical treatment in localized scleroderma and systemic sclerosis. Rheumatology. 2009;48: 213-21.
16. Ihn H, Sato S, Fujimoto M, Kikuchi K, Takehara K. Demonstration of interleukin-2, interleukin-4 and interleukin-6 in sera from patients with localized scleroderma. Arch Dermatol Res. 1995;287(2):193-7.
17. Kurzinski K, Torok KS. Cytokines profiles in localized scleroderma and relationship to clinical features. Citokine. 2011;55:157-64.